Your session is about to expire
← Back to Search
Evorpacept + Enfortumab Vedotin for Bladder Cancer
Study Summary
This trial tests a new drug combo to treat bladder cancer. It'll measure safety, how it works in the body, and how well it works.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is normal.My bone marrow is working well.I have been treated with a drug that boosts my immune system.I have moderate to severe nerve damage.My bladder cancer cannot be removed by surgery and has spread.I have brain metastases that are causing symptoms or are not under control.My liver is working well.I am physically able to care for myself.I have been treated with enfortumab vedotin or similar drugs before.I have an eye condition but it's under control with treatment.My diabetes has been under control for the last 3 months.I have been treated with platinum-based chemotherapy before.My bladder cancer has come back or gotten worse.I have never been treated with anti-CD47 or anti-SIRPα medications.
- Group 1: Evorpacept (ALX148) + Enfortumab Vedotin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any openings available for participation in this experiment?
"Clinical trials.gov confirms this trial is open to participants, with the first posting on November 2nd 2022 and last update taking place on January 23rd 2023."
What potential adverse reactions have been observed in individuals using Evorpacept (ALX148) + Enfortumab Vedotin?
"Given the limited safety and efficacy data, Evorpacept (ALX148) + Enfortumab Vedotin received a score of 1."
How many research locations are actively conducting this experiment within the city limits?
"This medicinal trial is open to enrollees at Moffitt Cancer Center in Tampa, University of Chicago Medicine in Chiacgo, and Massachusett's General in Boston. Additionally, 10 other US facilities are currently participating as well."
How many people have volunteered to take part in this clinical experiment?
"ALX Oncology Inc. is responsible for conducting the trial and has mandated that a minimum of 30 participants are necessary to generate valid results. Patients may find eligible sites at Moffitt Cancer Center, Tampa or University of Chicago Medicine in Illinois."
Share this study with friends
Copy Link
Messenger